Cocaine HCl
(Cocaine)ApprovedSmall molecule
Cocaine is a local anesthetic used medically to numb tissues during certain surgical procedures, particularly in nasal and ear surgery. It also constricts blood vessels, which helps reduce bleeding during these procedures.[2] Cocaine HCl is currently approved and in use across 1 indication[4].[1]
Cocaine HCl is one of 23 small molecule programs targeting Allergic Disease. It is currently in Approved.
1
Indications
28
Total Trials
0
Active Trials
22
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
12
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
23 competitors in Allergic Disease
#DrugCompanyPhaseTrials
1Taxol
TevaApproved
Allegra
CChattem
Approved
Zyrtec
KKenvue Brands
Approved
Foradil
ViatrisApproved
Xyzal
CChattem
Approved
Sudafed
KKenvue Brands
Approved
Celestone
SSchering-Plough
Approved
Decadron
AAspen Global Incorporated
Approved
Proair HFA
GGlaxo Dba Glaxosmithkline
Approved
Rayos
RRoxane Laboratories
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
AIN8 trials
Interaction3 trials
Drug3 trials
Cocaine Abuse3 trials
Cocaine Dependence2 trials
Complementary Combination Therapy for Cocaine Dependence
Completed·—·Phase 1·NCT02538744·45 enrolled
8 more indications
Cocaine Use Disorder1 trial
Anesthesia1 trial
Regulatory
FDA Approval Timeline[5]
Dec 14, 2017
GOPRELTO
NDA NDA209963
Jan 10, 2020
NUMBRINO
NDA NDA209575
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Cocaine HCl drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Cocaine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]